Role of Ketamine in Managing Opioid-Induced Hyperalgesia

Opioid-Induced Hyperalgesia

Volumn , Issue , 2016, Pages 124-133

  Vorobeychik, Yakov ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882596497     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420089004-12     Document Type: Chapter

References (71)

1. Vera-Portocarrero LP, Zhang ET, King T, et al. Spinal NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways. Pain 2007; 129(1-2): 35-45.
2. Gardell LR, Wang R, Burgess SE, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002; 22(15): 6747-6755.
3. Gardell LR, King T, Ossipov MH, et al. Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett 2006; 396(1): 44-49.
4. Meng ID, Harasawa I. Chronic morphine exposure increases the proportion of on-cells in the rostral ventromedial medulla in rats. Life Sci 2007; 80(20): 1915-1920.
5. Vera-Portocarrero LP, Zhang ET, Ossipov MH, et al. Descending facilitation from the rostral ventromedial medulla maintains nerve injury-induced central sensitization. Neuroscience 2006; 40(4): 1311-1320.
6. Xie JY, Herman DS, Stiller CO, et al. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci 2005; 25(2): 409-416.
7. Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002; 22(18): 8312-8323.
8. Inturrisi CE. The role of N-methyl-D-aspartate (NMDA) receptors in pain and morphine tolerance. Minerva Anestesiol 2005; 71(7-8): 401-403.
9. Mao J, Mayer DJ. Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathological pain. Ann N Y Acad Sci 2001; 933: 175-184.
10. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002; 100(3): 213-217.
11. Yenari MA, Bell TE, Kotake AN, et al. Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS-19755) in neurosurgery patients. Clin Neuropharmacol 1998; 21(1): 28-34.
12. Muir KW, Lees KR. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev 2003; 3: CD001244.
13. Hoyte L, Barber PA, Buchan AM, et al. The rise and fall of NMDA antagonists for ischemic stroke. Curr Mol Med 2004; 4(2): 131-136.
14. Wood PL. The NMDA receptor complex: a long and winding road to therapeutics. IDrugs 2005; 8(3): 229-235.
15. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-review of preclinical data. Neuropharmacology 1999; 38: 735-767.
16. MacDonald JF, Bartlett MC, Mody I, et al. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in culture mouse hippocampal neurons. J Physiol 1991; 432: 483-508.
17. Chizh BA, Cumberbatch MJ, Herrero JF, et al. Stimulus intensity, cell excitation and the N-methyl-D-aspartate receptor component of sensory responses in the rat spinal cord in vivo. Neuroscience 1997; 80: 251-265.
18. Chizh BA. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol 2007; 21(3): 259-271.
19. Jones MW, McClean M, Parsons CG, et al. The in vivo relevance of the varied channel-blocking properties of uncompetitive NMDA antagonists: test on spinal neurons. Neuropharmacology 2001; 41: 50-61.
20. Smith DG, Pekoe GM, Martin LL, et al. The interaction of ketamine with the opiate receptor. Life Sci 1980; 26(10): 789-795.
21. Smith DG, Bouchal RL, deSanctis CA, et al. Properties of the interaction between ketamine and opiate binding site in vivo and in vitro. Neuropharmacology 1987; 26: 1253-1260.
22. Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology 1997; 86(4): 903-917.
23. Kapur S, Seeman P. NMDA receptor antagonist ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2) receptors-implications for model of schizophrenia. Mol Psychiatry 2002; 7: 837-844.
24. Wood PB. A reconsideration of the relevance of systemic low-dose ketamine to the pathophysiology of fibromyalgia. J Pain 2006; 7(9): 611-614.
25. Chizh BA, Eide PK. Pain. In: Lodge D, Danysz W, Parsons CG, eds. Therapeutic Potential of Ionotropic Glutamate Receptor Antagonists and Modulators. Johnson City: F.P. Graham publishing Co., 2002: 263-300.
26. Chizh BA, Headley PM. NMDA antagonists and neuropathic pain-multiple drug targets and multiple uses. Curr Parm Des 2005; 11: 2977-2994.
27. Mikkelsen S, Ilkjaer S, Brennum J, et al. The effect of naloxone on hyperalgesia and ketamine-induced side effects in humans. Anesthesiology 1999; 90: 1539-1545.
28. 2 receptor”. Biol Psychiatry 2001; 50: 555.
29. Laulin JP, Maurette P, Corcuff JB, et al. The role of ketamine in preventing fentanylinduced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg 2002; 94(5): 1263-1269.
30. Célèrier E, Rivat C, Jun Y, et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 2000; 92(2): 447-456.
31. Van Elstraete AC, Sitbon P, Trabold F, et al. A single dose of intrathecal morphine in rats induces long-lasting hyperalgesia: The protective effect of prior administration of ketamine. Anesth analg 2005; 101: 1750-1756.
32. Richebe P, Rivat C, Laulin JP, et al. Ketamine improves the management of exaggerated postoperative pain observed in perioperative fentanyl-treated rats. Anesthesiology 2005; 102(2): 421-428.
33. Angst MS, Koppert W, Pahl I, et al. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 2003; 106: 49-57.
34. Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005; 103(1): 147-155.
35. Singla A, Stojanovic MP, Chen L, et al. A differential diagnosis of hyperalgesia, toxicity, and withdrawal from intrathecal morphine infusion. Anesth Analg 2007; 105(6): 1816-1819.
36. Okon T. Ketamine: an introduction for the pain and palliative medicine physician. Pain Physician 2007; 10: 493-500.
37. Fine PG. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage 1999; 17: 296-300.
38. Mercadante S, Arcuri E, Tirelli W, et al. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy. J Pain Symptom Manage 2000; 20: 246-252.
39. Good P, Tullio F, Jackson K, et al. Prospective audit of short-term concurrent ketamine, opioid and anti-inflammatory “triple-agent” therapy for episodes of acute on chronic pain. Intern Med J 2005; 35: 39-44.
40. Jackson K, Ashby M, Martin P, et al. “Burst” ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage 2001; 22: 834-842.
41. Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 1982; 71(5): 539-542.
42. Fitzgibbon EJ, Hall P, Schroder C, et al. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage 2002; 23: 165-170.
43. Kannan TR, Saxena A, Bhatnagar S, et al. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 2002; 23: 60-65.
44. Azevedo VM, Lauretti GR, Pereira NL, et al. Transdermal ketamine as an adjuvant for postoperative analgesia after abdominal gynecological surgery using lidocaine epidural blockade. Anesth Analg 2000; 91(6): 1479-1482.
45. Jiang JH, Kim DW, Sang NT. Peripheral glutamate receptors contribute to mechanical hyperalgesia in a neuropathic pain model of the rat. Neuroscience 2004; 128: 169-176.
46. Christoph T, Reissmuller E, Schiene K, et al. Antiallodynic effects of NMDA glycine B antagonists in neuropathic pain: possible peripheral mechanisms. Brain Res 2005; 1048: 218-227.
47. Koppert W, Zeck S, Blunk J, et al. The effects of intradermal fentanyl and ketamine on capsaicin-induced secondary hyperalgesia and flare reaction. Anesth Analg 1999; 89: 1521-1527.
48. Gammaitoni A, Gallagher RM, Welz-Bosna M. Topical ketamine gel: possible role in treating neuropathic pain. Pain Med 2000; 1: 97-100.
49. Ushida T, Tani T, Kanbara T, et al. Analgesic effects of ketamine ointment in patients with complex regional pain syndrome type 1. Reg Anesth PainMed 2002; 27: 524-528.
50. Lynch ME, Clark AJ, Sawynok J, et al. Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. J Pain 2005; 6(10): 644-649.
51. Clerc S, Vuilleumier H, Frascarolo P, et al. Is the effect of inguinal field block with 0.5% bupivacaine on postoperative pain after hernia repair enhanced by addition of ketorolac or S(+) ketamine? Clin J Pain 2005; 21(1): 101-105.
52. Ansermino M, Basu R, Vandebeek C, et al. Nonopioid additives to local anesthetics for caudal blockade in children: a systematic review. Paediatr Anaesth 2003; 13(7): 561-573.
53. Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004; 99(2): 482-495.
54. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am 2007; 91(2): 199-211.
55. Vielhaber A, Portenoy RK. Advances in cancer pain management. Hematol Oncol Clin North Am 2002; 16(3): 527-541.
56. Ossipov MH, Lai J, Vanderah TW, et al. Induction of pain facilitation by sustained opioid exposure: relationship to opioid antinociceptive tolerance. Life Sci 2003; 73: 783-800.
57. Fitzgibbon EJ, Viola R. Parenteral ketamine as an analgesic adjuvant for severe pain: development and retrospective audit of a protocol for a palliative care unit. J Palliat Med 2005; 8(1): 49-57.
58. Lossignol DA, Obiols-Portis M, Body JJ. Successful use of ketamine for intractable cancer pain. Support Care Cancer 2005; 13(3): 188-193.
59. Bell RF, Eccleston C, Kalso E. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage 2003; 26: 867-875.
60. Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management: preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 2000; 20(5): 358-373.
61. Jevtovic-Todorovic V, Wozniak DF, Benshoff ND, et al. A comparative evaluation of neurotoxic properties of ketamine and nitrous oxide. Brain Res 2001; 895: 246-247.
62. Stoltz M, Oehen HP, Gerber H. Histological findings after long-term infusion of intrathecal ketamine for chronic pain: a case report. J Pain Symptom Manage 1999; 18: 223-228.
63. Fisher K, Hagen NA. Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin: a case report. J Pain Symptom Manage 1999; 18: 61-66.
64. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother 2006; 60(7): 341-348.
65. Elia N, Tramer MR. Ketamine and postoperative pain-a quantitative systematic review of randomized trials. Pain 2005; 113(1-2): 61-70.
66. Jevtovic-Todorovic V, Olney JW. Neuroprotective agents. In: Evers AS, Mayes M, eds. Anesthetic pharmacology, physiologic principles and clinical practice. Philadelphia: Churchill Livingstone, 2004: 557-572.
67. Farber NB, Kim SH, Dikranian K, et al. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 2002; 7: 32-43.
68. Prommer E. Ketamine to control pain. J Palliat Med 2003; 6(3): 443-446.
69. 2- adrenergic agonists. Mol Psychiatry 1999; 4: 344-352.
70. Handa F, Tanaka M, Nishikawa T, et al. Effects of oral clonidine premedication on side effects of intravenous ketamine anesthesia: a randomized, double-blind placebocontrolled study. J Clin Anesth 2000; 12: 19-24.
71. Correll EC, Maleki J, Gracely EJ, et al. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med 2004; 5(3): 263-275.